Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marylore Chenel

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Investigational New Drugs|May 27, 2020
Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolationPhilippe B Pierrillas, Emilie Henin, Julien Ogier, et al.
Clinical Pharmacology and Therapeutics|March 31, 2022
How to Successfully Generate an Alternative Approach to a Thorough QT Study: GLPG1972 as an ExampleClaudia Meyer, Ines Dierick, Glenn Gauderat, et al.
Pharmaceutical Research|June 6, 2013
Application of hematological toxicity modeling in clinical development of abexinostat (S-78454, PCI-24781), a new histone deacetylase inhibitorQuentin Chalret du Rieu, Sylvain Fouliard, Anne Jacquet-Bescond, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 25, 2025
Model-Informed Drug Development of a Sustained Release Formulation of Flucytosine in the Treatment of Cryptococcal Meningitis: A Case Study Using Physiologically Based Pharmacokinetic ModelingJohanna Eriksson, Erik Sjögren, Jean-Yves Gillon, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 4, 2019
Prediction of Human Nonlinear Pharmacokinetics of a New Bcl-2 Inhibitor Using PBPK Modeling and Interspecies Extrapolation StrategyPhilippe B Pierrillas, Emilie Henin, Kathryn Ball, et al.
Cancer Research Communications|March 27, 2023
Mechanistic Modeling of the Interplay Between Host Immune System, IL-7 and UCART19 Allogeneic CAR-T Cells in Adult B-cell Acute Lymphoblastic LeukemiaThibaud Derippe, Sylvain Fouliard, Ibtissam Marchiq, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2018
Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of ImmunogenicityOlivia Campagne, Audrey Delmas, Sylvain Fouliard, et al.
Clinical Pharmacology and Therapeutics|January 14, 2018
Getting Innovative Therapies Faster to Patients at the Right Dose: Impact of Quantitative Pharmacology Towards First Registration and Expanding Therapeutic UseSatyaprakash Nayak, Oliver Sander, Nidal Al-Huniti, et al.
Clinical Pharmacology and Therapeutics|November 12, 2019
Transforming Translation Through Quantitative Pharmacology for High-Impact Decision Making in Drug Discovery and DevelopmentNeeraj Gupta, Dean Bottino, Ulrika S H Simonsson, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2013
Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase ISylvain Fouliard, Renata Robert, Anne Jacquet-Bescond, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Investigational New Drugs|May 27, 2020
Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolationPhilippe B Pierrillas, Emilie Henin, Julien Ogier, et al.
Clinical Pharmacology and Therapeutics|March 31, 2022
How to Successfully Generate an Alternative Approach to a Thorough QT Study: GLPG1972 as an ExampleClaudia Meyer, Ines Dierick, Glenn Gauderat, et al.
Pharmaceutical Research|June 6, 2013
Application of hematological toxicity modeling in clinical development of abexinostat (S-78454, PCI-24781), a new histone deacetylase inhibitorQuentin Chalret du Rieu, Sylvain Fouliard, Anne Jacquet-Bescond, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 25, 2025
Model-Informed Drug Development of a Sustained Release Formulation of Flucytosine in the Treatment of Cryptococcal Meningitis: A Case Study Using Physiologically Based Pharmacokinetic ModelingJohanna Eriksson, Erik Sjögren, Jean-Yves Gillon, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 4, 2019
Prediction of Human Nonlinear Pharmacokinetics of a New Bcl-2 Inhibitor Using PBPK Modeling and Interspecies Extrapolation StrategyPhilippe B Pierrillas, Emilie Henin, Kathryn Ball, et al.
Cancer Research Communications|March 27, 2023
Mechanistic Modeling of the Interplay Between Host Immune System, IL-7 and UCART19 Allogeneic CAR-T Cells in Adult B-cell Acute Lymphoblastic LeukemiaThibaud Derippe, Sylvain Fouliard, Ibtissam Marchiq, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2018
Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of ImmunogenicityOlivia Campagne, Audrey Delmas, Sylvain Fouliard, et al.
Clinical Pharmacology and Therapeutics|January 14, 2018
Getting Innovative Therapies Faster to Patients at the Right Dose: Impact of Quantitative Pharmacology Towards First Registration and Expanding Therapeutic UseSatyaprakash Nayak, Oliver Sander, Nidal Al-Huniti, et al.
Clinical Pharmacology and Therapeutics|November 12, 2019
Transforming Translation Through Quantitative Pharmacology for High-Impact Decision Making in Drug Discovery and DevelopmentNeeraj Gupta, Dean Bottino, Ulrika S H Simonsson, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2013
Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase ISylvain Fouliard, Renata Robert, Anne Jacquet-Bescond, et al.
Pageof 6